最新ニュース Insmed (NASDAQ:INSM) 株価情報

INSMED INC

Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Inc

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $110 to $109.

News

Price Target

Analyst Ratings

INSM

UBS Maintains Buy on Insmed, Lowers Price Target to $109

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 6.96% on an annualized basis producing an average annual return of 21.46%. Currently, Insmed has a market capitalization of $11.88 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 5 years ago, it would be worth $2,648.68 today based on a price of $65.63 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746808300_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

WIIM

Insmed shares are trading lower after the company reported worse-than-expected Q1 earnings and reaffirmed full-year guidance below estimates.

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) affirms FY2025 sales outlook from $405.00 million-$425.00 million to $405.00 million-$425.00 million vs $467.80 million estimate.

Guidance

Insmed Affirms FY2025 Sales Guidance of $405.00M-$425.00M vs $467.80M Est

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.42) per share which missed the analyst consensus estimate of $(1.33) by 6.77 percent. This is a 33.96 percent decrease over losses of $(1.06) per share from the same period last year. The company reported quarterly sales of $92.82 million which beat the analyst consensus estimate of $92.08 million by 0.81 percent. This is a 22.94 percent increase over sales of $75.50 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Insmed Q1 EPS $(1.42) Misses $(1.33) Estimate, Sales $92.82M Beat $92.08M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$42.00</td>
<td>$31.6K</td>
<td>1.4K</td>
<td>3.6K</td>
</tr>
<tr>
<td>ALDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.50</td>
<td>$62.2K</td>
<td>973</td>
<td>2.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$83.00</td>
<td>$187.0K</td>
<td>24</td>
<td>1.0K</td>
</tr>
<tr>
<td>KNSA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$20.00</td>
<td>$42.7K</td>
<td>308</td>
<td>299</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$41.0K</td>
<td>5.0K</td>
<td>286</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.00</td>
<td>$30.0K</td>
<td>5.1K</td>
<td>200</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$72.50</td>
<td>$31.9K</td>
<td>2.7K</td>
<td>197</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$77.4K</td>
<td>29.7K</td>
<td>115</td>
</tr>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$27.1K</td>
<td>434</td>
<td>104</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$480.00</td>
<td>$50.9K</td>
<td>849</td>
<td>63</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bullish, expiring in 4 day(s) on May 9, 2025. This event was a transfer of 80 contract(s) at a $42.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $31.6K, with a price of $395.0 per contract. There were 1486 open contracts at this strike prior to today, and today 3666 contract(s) were bought and sold. 
• For ALDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 1778 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $62.2K, with a price of $35.0 per contract. There were 973 open contracts at this strike prior to today, and today 2028 contract(s) were bought and sold. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on May 23, 2025. Parties traded 1000 contract(s) at a $83.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $187.0K, with a price of $187.0 per contract. There were 24 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• Regarding KNSA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>), we observe a call option sweep with bullish sentiment. It expires in 74 day(s) on July 18, 2025. Parties traded 50 contract(s) at a $20.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $42.7K, with a price of $855.0 per contract. There were 308 open contracts at this strike prior to today, and today 299 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bullish, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 79 contract(s) at a $80.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $41.0K, with a price of $520.0 per contract. There were 5034 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a call option trade that happens to be bearish, expiring in 137 day(s) on September 19, 2025. This event was a transfer of 200 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $150.0 per contract. There were 5132 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be neutral, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 49 contract(s) at a $72.50 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $658.0 per contract. There were 2748 open contracts at this strike prior to today, and today 197 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a put option sweep with bullish sentiment. It expires in 256 day(s) on January 16, 2026. Parties traded 113 contract(s) at a $30.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $77.4K, with a price of $686.0 per contract. There were 29726 open contracts at this strike prior to today, and today 115 contract(s) were bought and sold. 
• For CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 28 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $27.1K, with a price of $970.0 per contract. There were 434 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bearish sentiment. It expires in 11 day(s) on May 16, 2025. Parties traded 7 contract(s) at a $480.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $50.9K, with a price of $7280.0 per contract. There were 849 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALDX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KNSA

10 Health Care Stocks Whale Activity In Today's Session

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 4.19% since its last report. The company recently reported that it has 15.12 million shares sold short, which is 8.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746126028_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 6.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Insmed Gaining or Losing Market Support?

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 3.02% on an annualized basis producing an average annual return of 13.16%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $3,284.86 today based on a price of $67.90 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745591414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Insmed Reveals Redemption Of All $569.5M Of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo—
—Brensocatib 25 mg is the First Investigational Therapy for Bronchiectasis to Show a Statistically Significant Reduction in the Rate of Lung Function Decline—
—Brensocatib is Currently Under Priority Review with the U.S. Food and Drug Administration—
BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the New England Journal of Medicine (NEJM). The landmark ASPEN study is the largest clinical trial ever conducted in bronchiectasis, a serious, chronic, and progressive inflammatory pulmonary disease that today has no approved therapies.

Biotech

General

Insmed Announces New England Journal Of Medicine Publishes Results From Its Pivotal Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis; Largest Global Clinical Trial Ever Conducted In Bronchiectasis Demonstrates Statistically Significant And Clinically Meaningful Reduction In Frequency Of Pulmonary Exacerbations Versus Placebo

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>ServiceTitan, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) stock jumped 22.55% &nbsp;after it announced a strategic partnership with Cobalt Service Partners to power 12 commercial access solutions brands with<a href="https://www.benzinga.com//node/44817937" target="_blank" rel="noreferrer noopener"> its business management software</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares were up 22.13%.</li>
<li>YPF Sociedad Anonima (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) shares increased 19.94% after HSBC analyst Liyanna Yang upgraded the stock from Reduce to Hold and raised the <a href="https://www.benzinga.com/quote/ypf/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$21&nbsp;to&nbsp;$33</a>.</li>
<li>Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;stock rose 16.51% after the U.S. healthcare giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control <a href="https://www.benzinga.com//node/44860903" target="_blank" rel="noreferrer noopener">with&nbsp;diet and exercise alone</a>.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares grew 16.47%  after the company hinted it might resume purchasing Bitcoin (CRYPTO: BTC/USD) <a href="https://www.benzinga.com//node/44789931">after a week-long pause</a>.</li>
<li>America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>)&nbsp;stock upped 15.88% after HSBC analyst Madhvendra Singh upgraded the stock from Hold to Buy and raised <a href="http://benzinga.com/quote/amx/analyst-ratings" target="_blank" rel="noreferrer noopener">its price forecast from&nbsp;$15.5&nbsp;to&nbsp;$17.5</a>.</li>
<li>Ericsson&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares upped 14.91% after the company reported&nbsp;first-quarter results. Additionally, the company and Bell Canada announced the successful test of AI-native link adaptation to <a href="https://www.benzinga.com//node/44823834" target="_blank" rel="noreferrer noopener">boost network speed and efficiency</a>.</li>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) stock rose 12.10%.</li>
<li>Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) stock surged 11.76% after Truist Securities analyst Neal Dingmann&nbsp;raised its price forecast from&nbsp;$238&nbsp;to&nbsp;$242&nbsp;<a href="https://www.benzinga.com/quote/fang/analyst-ratings" target="_blank" rel="noreferrer noopener">and maintained a Buy rating</a>.</li>
<li>Neurocrine Biosciences Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)&nbsp;shares increased 11.75% after some <a href="https://www.benzinga.com//node/44818760" target="_blank" rel="noreferrer noopener">analysts upgraded the stock</a>.</li>
</ol>
Photo by DCStockPhotography via Shutterstock

Equities

Large Cap

Movers

ERIC

FANG

MSTR

NBIX

SMMT

TTAN

In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 5 years by 14.56% on an annualized basis producing an average annual return of 28.37%. Currently, Insmed has a market capitalization of $12.86 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 5 years ago, it would be worth $367.67 today based on a price of $71.07 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744752627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 3.48% on an annualized basis producing an average annual return of 14.26%. Currently, Insmed has a market capitalization of $14.37 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $3,741.11 today based on a price of $79.38 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742913010_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $92 to $96.

B of A Securities Maintains Buy on Insmed, Raises Price Target to $96

13 analysts have shared their evaluations of Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 5.28% from the previous average price target of $93.67.
<img src="https://www.benzinga.com/files/images/story/2025/1742418025_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Insmed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$101.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Insmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Insmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insmed's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Insmed analyst ratings.</a>
<h2>Discovering Insmed: A Closer Look</h2>
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
<h3>Breaking Down Insmed's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Insmed's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 24.79%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Insmed's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -225.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Insmed's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -61.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Insmed's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Insmed's debt-to-equity ratio stands notably higher than the industry average, reaching 4.03. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Insmed Through The Eyes Of 13 Analysts

RBC Capital analyst Leonid Timashev reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform and maintains $100 price target.

RBC Capital Reiterates Outperform on Insmed, Maintains $100 Price Target

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $105 to $110.

UBS Maintains Buy on Insmed, Raises Price Target to $110

Amid an especially volatile <a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">start to 2025</a>, small-cap stocks have struggled. Are they now a buy at depressed valuations?
Russell 2000: The Russell 2000, as reflected by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), has dropped nearly 15% since December 2024. This constitutes a market correction.
The Trump Administration has embraced domestic and foreign policies that Former Treasury Secretary&nbsp;Larry Summers&nbsp;<a href="https://www.benzinga.com/markets/equities/25/02/43649860/larry-summers-and-peter-schiff-warn-of-rising-inflation-risks-as-markets-slash-fed-rate-cut-expectations-most-sensitive-moment">labels as inflationary</a>. Higher prices could lead to higher interest rates, which disproportionately affect smaller companies with floating-rate debt.
The Russell index <a href="https://research.ftserussell.com/Analytics/FactSheets/Home/DownloadSingleIssue?issueName=US2000USD&amp;isManual=True">contains</a> 2,000 companies with an average market cap of around $1 billion. Higher-weighted components are likely to have outperformed the rest of the index and are not necessarily representative of the entire Russell 2000. Still, they provide a glimpse into how investors are valuing small-cap companies.
Here&#8217;s how the top stocks in the IWM have performed since the ETF&#8217;s correction began in December 2024:
Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)
<ul>
<li>Dec. 2, 2024, Price: $150.92​</li>
<li>March 6, 2025, Price: $138.11​</li>
<li>Percentage Change: -8.49%</li>
</ul>
Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>)
<ul>
<li>Dec. 2, 2024, Price: $72.42​</li>
<li>March 6, 2025, Price: $75.02​</li>
<li>Percentage Change: +3.59%​</li>
</ul>
Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>)
<ul>
<li>Dec. 2, 2024, Price: $91.60​</li>
<li>March 6, 2025, Price: $74.81</li>
<li>Percentage Change: -18.33%​</li>
</ul>
SouthState Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NASDAQ">SSB</a>)
<ul>
<li>Dec. 2, 2024, Price: $109.35</li>
<li>March 6, 2025, Price: $92.37</li>
<li>Percentage Change: -15.53%​</li>
</ul>
FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>)
<ul>
<li>Dec. 2, 2024, Price: $166.8​</li>
<li>March 6, 2025, Price: $108.2​8</li>
<li>Percentage Change: -35.08%​</li>
</ul>
Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)
<ul>
<li>Dec. 2, 2024, Price: $24.16</li>
<li>March 6, 2025, Price: $18.66</li>
<li>Percentage Change: -22.76%​</li>
</ul>
Applied Industrial Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>)
<ul>
<li>Dec. 2, 2024, Price: $272.91</li>
<li>March 6, 2025, Price: $229.00</li>
<li>Percentage Change: -16.09%​</li>
</ul>
Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)
<ul>
<li>Dec. 2, 2024, Price: $47.80​</li>
<li>March 6, 2025, Price: $42.07</li>
<li>Percentage Change: -11.99%​</li>
</ul>
Ufp Industries Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPI#NASDAQ">UFPI</a>) and&nbsp;Fluor Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) are also among the ETF&#8217;s top holdings.
Benzinga Edge evaluates stocks on a valuation, momentum and growth basis.
UFP, a holding company based in Grand Rapids, Michigan, performs well under the value criterion, scoring 78.64 out of 100. However, the stock does not have momentum, scoring 32.82. It is also not the fastest-growing company, grading 33.35. The stock is down 20.5% since Dec. 2, 2024.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/UFPI"><img loading="lazy" decoding="async" width="1024" height="229" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-1024x229.png" alt="" class="wp-image-812940" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-1024x229.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-300x67.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-768x172.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM.png 1314w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Fluor, an engineering and construction firm, rates high according to its intrinsic value, scoring at 93.6. Still, recent price action indicates its growth and momentum prospects are not high, scoring 15.32 and 29.26, respectively. The stock is down 33.6% since Dec. 2, 2024.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/FLR"><img loading="lazy" decoding="async" width="1024" height="232" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-1024x232.png" alt="" class="wp-image-812935" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-1024x232.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-300x68.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-768x174.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM.png 1322w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<ul>
<li>Unlock the rest of the BZ Edge Rankings and see how <a href="https://www.benzinga.com/quote/fn">another small-cap stock stacks up</a>.</li>
</ul>
S&amp;P 500 Comparison: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks 500 of the largest U.S. companies, has fared slightly better than the Russell 2000. The index is down around 2% since Dec. 2, 2024.
On an earnings basis, investors are trading the S&amp;P 500 at a much higher multiple than the Russell 2000. The S&amp;P as a whole is trading 21.63 times above earnings compared to the small-cap index&#8217;s 14.84 times. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44174230/short-seller-targets-gorilla-technology-group-stock-investors-take-profits">Short Seller Targets Gorilla Technology Group Stock, Investors Take Profits</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Broad U.S. Equity ETFs

ETFs

CRDO

FTAI

PCVX

RKLB

UFPI

Are Small-Cap Stocks A Buy After Russell 2000 Correction?

Press Releases

Insmed To Present at March 2025 Investor Conferences

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Offerings

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Insmed To Present at the BofA Securities 2025 Health Care Conference

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Comments

Insmed

ニュース

最新ニュース Insmed (NASDAQ:INSM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル